Press Releases

WATERTOWN, Mass. , June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

WATERTOWN, Mass. , June 14, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

– Data demonstrate that ImmTOR enhances the tolerogenic environment in the liver– – ImmTOR data show induction of a tolerogenic phenotype in all major hepatic antigen presenting cell populations and is protective in an acute model of autoimmune hepatitis                    –Publication further

WATERTOWN, Mass. , May 25, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021 SEL-212 enrollment on track with topline data from DISSOLVE phase 3 program expected in second half of 2022 IND filing for IgA nephropathy program expected by the end of 2021 IND filing

WATERTOWN, Mass. , May 06, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to

WATERTOWN, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming

– Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains on track – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C.

WATERTOWN, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

-   First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - -   Methylmalonic acidemia   (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in